Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19707287&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention Parikh SV; Keeley ECVasc Health Risk Manag 2009[]; 5 (ä): 677-91The wide variety of anticoagulant and antiplatelet agents available for clinical use has made choosing the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention a complex task. While there is no single best regimen, from a risk-benefit ratio standpoint, particular regimens may be considered optimal for different patients. We review the mechanisms of action for the commonly prescribed antithrombotic medications, summarize pertinent data from randomized trials on their use in acute coronary syndromes, and provide an algorithm (incorporating data from these trials as well as risk assessment instruments) that will help guide the decision-making process.|*Patient Selection[MESH]|Acute Coronary Syndrome/*therapy[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|Algorithms[MESH]|Angioplasty, Balloon, Coronary/*adverse effects[MESH]|Anticoagulants/adverse effects/*therapeutic use[MESH]|Decision Support Techniques[MESH]|Drug Therapy, Combination[MESH]|Evidence-Based Medicine[MESH]|Female[MESH]|Fibrinolytic Agents/adverse effects/*therapeutic use[MESH]|Hemorrhage/chemically induced[MESH]|Humans[MESH]|Male[MESH]|Middle Aged[MESH]|Platelet Aggregation Inhibitors/adverse effects/*therapeutic use[MESH]|Risk Assessment[MESH]|Risk Factors[MESH]|Thrombosis/etiology/*prevention & control[MESH]|Treatment Outcome[MESH] |
